Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
Murtuza Bharmal,1 Mairead Kearney,1 Ying Zheng,2 Hemant Phatak21Global Evidence and Value Development, Merck Healthcare KGaA, Darmstadt, Germany; 2US Health Economics and Outcomes Research, EMD Serono, Inc, Rockland, MA, USAObjective: To estimate the budget impact of avelumab as a treatment option f...
Saved in:
Main Authors: | Bharmal M (Author), Kearney M (Author), Zheng Y (Author), Phatak H (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
by: Kongnakorn T, et al.
Published: (2019) -
Re-induction of avelumab for patients with metastatic merkel cell carcinoma
by: Goto Hiroyuki, et al.
Published: (2023) -
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma
by: Ping Hu, et al.
Published: (2024) -
Merkel cell carcinoma in the context of follicular lymphoma treated with radiation and avelumab
by: Aya Nishizawa, MD, PhD, et al.
Published: (2024) -
Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response
by: Alexandra Picard‐Gauci, et al.
Published: (2022)